First-in-Human trial tests re-engineered immune cells to fight aggressive brain cancer
NCT ID NCT06964737
Summary
This early-stage study is testing a new type of personalized cell therapy for adults with aggressive brain tumors that have returned after prior treatment. Doctors take a patient's own immune cells, modify them in a lab to better target the cancer, and then infuse them back into the brain. The main goal is to find a safe and tolerable dose, while also checking for any early signs that the treatment might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for WHO GRADE 4 GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ohio State University Comprehensive Cancer Center
RECRUITINGColumbus, Ohio, 43210, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.